[ad_1]
Michelle Corral
Vice President of Investor Relationship & Company Communications
Hello, everybody, and thanks for becoming a member of us right this moment. I am Michelle Corral, Vice President of Company Communications and Investor Relations at Tenaya. In the present day, we’re excited to current preliminary knowledge from Cohort 1 of the RIDGE-1 Section Ib/II scientific trial of TN-401 gene remedy for the potential therapy of PKP2-associated arrhythmogenic proper ventricular cardiomyopathy or in any other case often called ARVC.
On the decision with me are Faraz Ali, Tenaya’s Chief Govt Officer; Dr. Kathy Ivey, our SVP of Analysis; and Dr. Whit Tingley, Tenaya’s Chief Medical Officer.
Whereas the info we’re disclosing can be described in full verbally, please be aware that in the course of the course of right this moment’s name, we can be making references to slides. A PDF file of those slides is offered on the Tenaya web site within the IR part below Occasions and Shows.
As a reminder, the knowledge mentioned throughout this name will embody forward-looking statements, which characterize the corporate’s view as of right this moment, December 11, 2025. These statements contain sure assumptions, and we warning traders to not place undue reliance on this data. Please seek advice from right this moment’s press launch in addition to our filings with the SEC for data regarding danger elements that would trigger precise outcomes to vary materially from these expressed or implied by these statements.
As well as, I would wish to remind people that we’re unable to take questions on right this moment’s name because of the launch
[ad_2]
